OAM
VIR icon

OP Asset Management’s Vir Biotechnology VIR Stock Holding History

OP Asset Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
152,257
+39,229
+35% +$373K 0.02% 532
2026
Q1 		$1.01M Buy
+113,028
New +$901K 0.01% 602

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

OP Asset Management's VIR Position: Q2 2026 in Review

OP Asset Management increased its Vir Biotechnology (VIR) stake by 35% in Q2 2026, buying an estimated $373K and bringing the position to 152,257 shares worth $1.55M. The position accounts for 0.02% of the portfolio, ranked #532.

OP Asset Management first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 238 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • OP Asset Management held 152,257 shares of Vir Biotechnology worth $1.55M as of Q2 2026.
  • OP Asset Management bought 39,229 Vir Biotechnology shares in Q2 2026, an estimated $373K.
  • Vir Biotechnology made up 0.02% of OP Asset Management's portfolio in Q2 2026, its #532 holding.
  • OP Asset Management first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 238 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on OP Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.